Despite recent advances for patients with unresectable stage III non-small cell lung cancer (NSCLC) with the addition of durvalumab (PD-L1 inhibitor) consolidation after concurrent chemoradiation (CRT), only a fraction of patients experienced durable progression-free survival (PFS)1,2. Here, CD274 is linked to non-small cell lung carcinoma.